ALK positive lung cancer

July 11, 2017

FDA Grants Orphan Drug Status to TPX-0005 for Non-small Cell Lung Cancers with Gene Mutations

News

U.S. regulators have granted orphan drug status to TP Therapeutics’ TPX-0005 as a treatment for non-small cell lung cancers with certain gene mutations, according to a company press release. The Federation Drug ... Read more

May 15, 2015

EMD Serono and Pfizer To Promote NSCLC Therapy

Lung cancer News, News

Biopharmaceutical company EMD Serono has initiated co-promotion of XALKORI (crizotinib), an FDA-approved treatment for patients with non-small cell lung cancer (NSCLC), in collaboration with the company that produced the therapy, Pfizer. The ... Read more

March 5, 2015March 5, 2015

Zykadia Recommended For EU Approval To Treat ALK+ NSCLC Patients

News

Novartis recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a favorable opinion concerning Zykadia (ceritinib) to address treatment for adult patients suffering with anaplastic ... Read more

September 29, 2014September 29, 2014

NCI/FDA Lung Cancer Workshop Leads To LUNG-MAP And ALCHEMIST Clinical Trials

Lung cancer News, News

Two of the most innovative lung cancer focused clinical studies launched recently, the Lung Cancer Master Protocol (Lung-MAP) and the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST), ... Read more

September 8, 2014September 8, 2014

Study Reveals New Drug Combination Targets for Lung Cancer

Lung cancer News, News

After surprising clinical observations of a patient with ALK fusion–positive lung cancer who had an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific antibody, a team of researchers from Vanderbilt ... Read more